A carregar...
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
BACKGROUND: In Germany, the clinical use of TNF-α inhibitors in the therapy of rheumatoid arthritis (RA) grew from 2 % of treated patients in 2000 to 20 % in 2008. In 2012, adalimumab was the bestselling drug in the statutory health insurance system with net expenditure of € 581 mio. OBJECTIVES: We...
Na minha lista:
| Publicado no: | Z Rheumatol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Medizin
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5127857/ https://ncbi.nlm.nih.gov/pubmed/27080399 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00393-016-0071-9 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|